for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vanda Pharmaceuticals Inc.

VNDA.O

Latest Trade

9.34USD

Change

0.00(0.00%)

Volume

733,526

Today's Range

9.20

 - 

9.74

52 Week Range

7.12

 - 

17.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.34
Open
9.67
Volume
733,526
3M AVG Volume
12.99
Today's High
9.74
Today's Low
9.20
52 Week High
17.85
52 Week Low
7.12
Shares Out (MIL)
54.65
Market Cap (MIL)
538.32
Forward P/E
26.48
Dividend (Yield %)
--

Next Event

Q3 2020 Vanda Pharmaceuticals Inc Earnings Release

Latest Developments

More

Vanda Says Enrollment In Phase 3 Gastroparesis Study Expected To Complete In H1 2021

Vanda Pharmaceuticals Posts Q2 Net Product Sales Of $62.2 Mln

FDA Accepts And Grants Priority Review Of Vanda's Applications For Hetlioz

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Industry

Biotechnology & Drugs

Contact Info

2200 Pennsylvania Ave NW Ste 300E

WASHINGTON, DC

20037-1754

United States

+1.202.7343400

http://www.vandapharma.com/

Executive Leadership

H. Thomas Watkins

Independent Chairman of the Board

Mihael Hristos Polymeropoulos

President, Chief Executive Officer, Director

Kevin Patrick Moran

Acting Chief Financial Officer, Vice President, Treasurer

Joakim Wijkstrom

Senior Vice President, Chief Marketing Officer

Timothy I. Williams

Senior Vice President, General Counsel, Secretary

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.3K
EPS (USD)

2017

-0.350

2018

0.480

2019

2.110

2020(E)

0.372
Price To Earnings (TTM)
4.72
Price To Sales (TTM)
2.24
Price To Book (MRQ)
1.25
Price To Cash Flow (TTM)
4.61
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
30.16
Return on Equity (TTM)
25.90

Latest News

Latest News

Vanda's experimental COVID-19 drug shows promise in interim trial data

COVID-19 patients with pneumonia improved faster when treated with Vanda Pharmaceuticals Inc's experimental therapy than those on placebo, the company said on Tuesday, citing an interim analysis of data from a late-stage study.

Vanda's experimental COVID-19 drug shows promise in interim trial data

COVID-19 patients with pneumonia improved faster when administered with its experimental therapy than those on placebo, Vanda Pharmaceuticals Inc said on Tuesday, citing an interim analysis of data from a late-stage study.

BRIEF-Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

* VANDA PHARMACEUTICALS INC - FEDERAL DISTRICT COURT IN WASHINGTON D.C. GRANTED VANDA'S MOTION TO DISMISS A FALSE CLAIMS ACT LAWSUIT FILED AGAINST CO Source text for Eikon: Further company coverage:

BRIEF-Vanda Pharmaceuticals CEO's Proposal On Clinical Trial Data Sharing, COVID-19 And Remdesivir

* VANDA PHARMACEUTICALS CEO'S PROPOSAL ON CLINICAL TRIAL DATA SHARING, COVID-19 AND REMDESIVIR

BRIEF-Vanda Pharmaceuticals- Reached Agreement With FDA To Resubmit Application For Hetlioz To Treat Patients With Smith-Magenis Syndrome

* VANDA PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON RESUBMISSION OF THE APPLICATION FOR HETLIOZ® FOR THE TREATMENT OF PATIENTS WITH SMITH-MAGENIS SYNDROME

BRIEF-Vanda Pharmaceuticals Begins Joint COVID-19 Study With University Of Washington Medicine

* VANDA PHARMACEUTICALS ANNOUNCES INITIATION OF "CALYPSO" TO STUDY THE ROLE OF GENETIC VARIATION IN COVID-19 INFECTIONS IN COLLABORATION WITH UNIVERSITY OF WASHINGTON MEDICINE

BRIEF-Vanda Pharmaceuticals, Northwell Health Conduct Trial In Patients With Severe Covid-19 Pneumonia

* VANDA PHARMACEUTICALS, NORTHWELL HEALTH CONDUCT ODYSSEY TRIAL IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA Source text for Eikon: Further company coverage:

BRIEF-Vanda Pharmaceuticals Inc. And The University Of Illinois At Chicago Announce Partnership To Identify Novel Antivirals Against Covid-19

* VANDA PHARMACEUTICALS INC. AND THE UNIVERSITY OF ILLINOIS AT CHICAGO ANNOUNCE PARTNERSHIP TO IDENTIFY NOVEL ANTIVIRALS AGAINST COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Vanda Pharmaceuticals Announces Initiation Of Odyssey

* VANDA PHARMACEUTICALS ANNOUNCES THE INITIATION OF ODYSSEY, AN FDA APPROVED CLINICAL STUDY OF TRADIPITANT IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19 PNEUMONIA

BRIEF-Vanda Says FDA Refused Filing Of sNDA For Hetlioz For Treatment Of Smith-Magenis Syndrome

* VANDA - RECEIVED LETTER FROM FDA IN WHICH FDA NOTIFIED CO OF ITS REFUSAL TO FILE CO'S SNDA FOR HETLIOZ FOR TREATMENT OF SMITH-MAGENIS SYNDROME

BRIEF-Vanda Pharmaceuticals Says James Kelly Notified Co Of His Resignation As Chief Financial Officer

* JAMES KELLY NOTIFIED COMPANY OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER

Humane Society backs Vanda's animal drug study case against FDA

The Humane Society of the United States is backing Vanda Pharmaceuticals Inc's fight against a U.S. Food and Drug Administration requirement that it conduct a study of a drug's risks to humans using dogs who would be euthanized at the end of the study.

Vanda loses bid to proceed with drug trial while FDA reconsiders hold

A federal judge ruled on Thursday that Vanda Pharmaceuticals Inc could not proceed with a human clinical trial for its gastrointestinal drug tradipitant while the U.S. Food and Drug Administration weighs requiring months of additional animal toxicity testing.

FDA fights Vanda bid to lift partial hold on human drug trial

The Food and Drug Administration is urging a judge to not allow Vanda Pharmaceuticals Inc to proceed with a human clinical drug trial while the agency reconsiders whether the drugmaker must also conduct a study on dogs who would need to be euthanized at the end of the trial.

Drugmaker Vanda sues FDA over required animal drug study

Biopharmaceutical company Vanda Pharmaceuticals Inc has sued the U.S. Food and Drug Administration, saying the regulator is forcing it to unnecessarily conduct a study of a drug it is developing on dogs who would need to be euthanized at it conclusion.

BRIEF-Vanda Pharmaceuticals Says Hetlioz Is Effective In Treating Jet Lag During Transatlantic Travel

* HETLIOZ® (TASIMELTEON) EFFECTIVE IN TREATING JET LAG DURING TRANSATLANTIC TRAVEL

BRIEF-Vanda Pharmaceuticals Inc Reports Qtrly EPS Of $0.06

* VANDA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Patent on Vanda schizophrenia drug upheld by appeals court

A federal appeals court on Friday ended a bid by West-Ward Pharmaceuticals Corp to invalidate a patent on Vanda Pharmaceutical Inc's schizophrenia drug Fanapt and bring a lower-cost generic version to market.

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT

BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule

* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up